Nicotinamide Riboside Mitigates Antiphospholipid Antibody‐Induced Dysfunction in Human Trophoblast Cells
American Journal of Reproductive Immunology · 2026
DOI: 10.1111/aji.70205 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Reproductive Immunology, 2026. Verfasst von Abigail C Fischer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Trophoblasts, Antibodies, Antiphospholipid, Niacinamide, Antiphospholipid Syndrome. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Department of Defense (VMA).
Abstract (Originalsprache)
Problem Obstetric antiphospholipid syndrome (APS) is characterized by the presence of circulating anti‐phospholipid antibodies (aPL), which disrupt early placentation and contribute to adverse pregnancy outcomes including pregnancy loss and preterm birth. aPL, specifically those targeting beta 2 glycoprotein 1 (β 2 GPI), interact with placental trophoblast cells and induce inflammation, disrupt angiogenic factor production, and reduce cell migration. In addition, aPL have been shown to promote a state of oxidative stress in trophoblast cells and in APS patients. This study aimed to investigate if the antioxidant, nicotinamide riboside (NR), could mitigate the negative effects of aPL on trophoblast cells. Method of Study The human first‐trimester trophoblast cell line, Sw.71, was treated with or without aPL in the presence or absence of NR. Trophoblast supernatants were measured by ELISA for pro‐inflammatory cytokines/chemokines and angiogenic factors. Cell migration was measured using a two‐chamber colorimetric assay. ROS production was measured using a fluorescence assay.
Results
NR blocked aPL‐induced trophoblast inflammation and ROS production, and reversed the effects of aPL on trophoblast angiogenic factor production. However, NR was unable to rescue aPL‐induced trophoblast migratory dysfunction.
Conclusion
NR mitigated some, but not all, aPL‐induced trophoblast dysfunction. This provides new insight into the role of antioxidant therapies on aPL‐induced pregnancy complications, and a possible new avenue of managing obstetric APS to explore further.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University, New Haven, Connecticut, USA.
- Department of Obstetrics & Gynecology, University of Auckland, Auckland, New Zealand.
ORCID-Profile: Hanah M Georges, Vikki M Abrahams
Förderung
- Department of Defense (VMA)
Zitieren
APA
Fischer, A. C., Georges, H. M., Jones, D. M., Chamley, L. W., & Abrahams, V. M. (2026). Nicotinamide Riboside Mitigates Antiphospholipid Antibody‐Induced Dysfunction in Human Trophoblast Cells. American Journal of Reproductive Immunology. https://doi.org/10.1111/aji.70205
Vancouver
Fischer AC, Georges HM, Jones DM, Chamley LW, Abrahams VM. Nicotinamide Riboside Mitigates Antiphospholipid Antibody‐Induced Dysfunction in Human Trophoblast Cells. American Journal of Reproductive Immunology. 2026. doi:10.1111/aji.70205
BibTeX
@article{Fischer2026,
author = {Fischer, Abigail C and Georges, Hanah M and Jones, Deidre M and Chamley, Lawrence W and Abrahams, Vikki M},
title = {Nicotinamide Riboside Mitigates Antiphospholipid Antibody‐Induced Dysfunction in Human Trophoblast Cells},
journal = {American Journal of Reproductive Immunology},
year = {2026},
doi = {10.1111/aji.70205}
}
EUVIMED